Serum IL-6 level in breast cancer surgery: evaluating the addition of hydrocortisone on two anaesthetic regimens

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR201304000509378

Enrollment

100

Registered

2013-02-23

Start date

2013-03-02

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer Skin and Connective Tissue Diseases effect of adding hydrocortisone on two anaesthetic regimens on post operative IL-6 levelin breast cancer patients

Interventions

general anesthesia

thoracic paravertebral block

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: ASA I-II women who undergo conservative breast cancer surgery

Exclusion criteria

Exclusion criteria: Patients with endocrine or metabolic disorders, diabetes, obesity (Body Mass Index >30 kg/m2), history of CNS diseases and patients under current or recent medication affecting the sympathetic response or the hormonal secretion were excluded from the study.

Design outcomes

Primary

Measure	Time frame
decrease level of IL-6	—

Secondary

Measure	Time frame
type of anaesthesia possibly affecting IL-6	—

Countries

Egypt

Contacts

Public Contactmohamed;Ahmed elakany;Talha

lecturer of anesthesia-medical research institute Alexandria university;Lecturer of surgery

mlakany@yahoo.com;dr_shereif@hotmail.com01001459756;00201001459756

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026